Metabolite technology developed in the College of Medicine – Tucson has been licensed to startup MetFora. Researchers at the University of Arizona College of Medicine – Tucson have developed a new way to provide earlier diagnosis of lung disease. The method involves analyzing metabolites, small molecules that are produced through cellular metabolic reactions. When normal...
Tag: <span>Lung disease</span>
Post
Researchers find new target to combat lung disease
by University of Technology, Sydney Professor Phil Hansbro, Director of the Centenary UTS Centre for Inflammation. Credit: Supplied by Centenary UTS Centre for Inflammation Research led by the Centenary Institute and University of Technology Sydney (UTS) has identified a small RNA molecule called microRNA-21 as a therapeutic target and its inhibition as a potential treatment...
Post
Computerised image analysis identifies new subtype of debilitating lung disease
by University College London Computed tomography images of the upper lungs. The image on the left shows areas of thickening in the periphery of the lungs. The same regions are highlighted in red on the right image following computer analysis of the computed tomography scan. Areas in red correspond to pleuroparenchymal fibroelastosis, a previously under-reported pattern...
Post
Immune cell implicated in development of lung disease following viral infection
by Julia Evangelou Strait, Washington University School of Medicine in St. Louis A new study from Washington University School of Medicine implicates a type of immune cell — called a dendritic cell — in the development of chronic lung diseases that can follow after a respiratory viral infection. Shown is a stained section of mouse lung....
Post
International recommendations for nontuberculous mycobacteria
GERMAN CENTER FOR INFECTION RESEARCH NTMs are closely related to tuberculosis bacteria and can (but do not need to) cause infectious diseases in humans. They are called “nontuberculous mycobacteria” (NTMs) to distinguish them from tuberculosis bacteria. There are approximately 200 different species and subspecies of these bacteria. Patients with bronchiectasis (dilation of the airways) are...
Post
Researchers identify key mechanisms involved in pulmonary fibrosis development
by Charité – Universitätsmedizin Berlin CT images and tissue sections show how healthy, air-filled tissue is replaced by thickened, stiff connective tissue. Credit: Leitz/Charité Working alongside research groups from Heidelberg, researchers from Charité – Universitätsmedizin Berlin have elucidated the novel disease processes involved in the development of pulmonary fibrosis. They were able to show that...
Post
Research points to possible target to treat idiopathic pulmonary fibrosis, or IPF
This study included preclinical experiments and use of bronchoalveolar cells from IPF patients UNIVERSITY OF ALABAMA AT BIRMINGHAM BIRMINGHAM, Ala. – Long-held dogma says lung fibrosis in diseases like idiopathic pulmonary fibrosis, or IPF, results from recurrent injury to alveolar epithelium that is followed by dysregulated repair. Research at the University of Alabama at Birmingham uproots that paradigm, and it suggests a possible treatment target for IPF. A....
Post
Liver damage from drinking may one day be REVERSIBLE: Scientists are developing a drug to undo tissue scarring in lung and liver disease
Scar tissue forms in the place of healthy tissue in organs This process is called cirrhosis in the liver and fibrosis in the lungs Its a hallmark of liver and lung diseases triggered by excessive drinking and smoking This damage is currently irreversible, incurable and can prove fatal But Mayo Clinic researchers discovered they can block two proteins to tell scar tissue precursors to do the opposite, removing and breaking down...
Post
High fiber, yogurt diet associated with lower lung cancer risk
VANDERBILT UNIVERSITY MEDICAL CENTER A diet high in fiber and yogurt is associated with a reduced risk for lung cancer, according to a study by Vanderbilt University Medical Center researchers published in JAMA Oncology. IMAGE: SENIOR AUTHOR XIAO-OU SHU, MD, PHD, MPH, INGRAM PROFESSOR OF CANCER RESEARCH, ASSOCIATE DIRECTOR FOR GLOBAL HEALTH AND CO-LEADER OF...
Post
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Interstitial lung disease (ILD) is the leading cause of death among people with systemic sclerosis (SSc) or scleroderma Approval is based on results from the Phase III SENSCIS® study, the largest randomized controlled trial in SSc-ILD patients Ofev is already approved in the U.S. and more than 70 countries for the treatment of idiopathic pulmonary fibrosis (IPF) Ridgefield, Conn., September 06, 2019 – Boehringer...